Skip to main content
Erschienen in: Clinical and Experimental Medicine 2/2018

14.12.2017 | Review Article

Systemic lupus erythematosus and ocular involvement: an overview

verfasst von: Rosanna Dammacco

Erschienen in: Clinical and Experimental Medicine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease of undefined etiology and with remarkably heterogeneous clinical features. Virtually any organ system can be affected, including the eye. SLE-related eye involvement can be diagnosed in approximately one-third of the patients and is usually indicative of disease activity. An early diagnosis and the adoption of suitable therapeutic measures are necessary to prevent sight-threatening consequences, especially in patients with juvenile SLE. Periocular lesions, such as eyelid involvement and orbital inflammation, are relatively rare and, in case of orbital masses, may require a biopsy control. Keratoconjunctivitis sicca or secondary Sjögren’s syndrome is the most frequent ophthalmic manifestation of SLE. According to its variable severity, lubricating tear drops may be sufficient in mild cases, whereas cyclosporine-A ophthalmic solution, glucocorticoids (GCs), methotrexate, and/or other immunosuppressive drugs may be required in the more severe cases. Partial occlusion of the lacrimal punctum by thermal cautery is rarely applied. Although uncommon, episcleritis and scleritis can sometimes be detected as an initial finding of SLE and reveal themselves as moderate to intense ocular pain, redness, blurred vision, and lacrimation. Unilateral or more often bilateral retinopathy is responsible for visual loss of variable severity and is ascribed to vasculitis of the retinal capillaries and arterioles. In addition to the combined treatment suitable for all patients with active SLE, intravitreal bevacizumab should be considered in cases of severe vaso-occlusive retinopathy and laser photocoagulation in cases of neovascularization. Purtscher-like retinopathy is likely ascribable to the formation of microemboli that results in retinal vascular occlusion and microvascular infarcts. Choroidal disease is characterized by monolateral or bilateral blurred vision. Because of the choroidal effusion, retinal detachment and secondary angle-closure glaucoma may occur. Ischemic optic neuropathy is characterized by acute-onset and progressive binocular visual impairment as a consequence of occlusion of the small vessels of the optic nerves due to immune complex vasculitis. Intravenous GC boluses followed by oral GCs and/or, in case of recurrence, intravenous cyclophosphamide and/or rituximab are commonly employed. Neovascularization can be treated by intravitreal bevacizumab and progression of retinal ischemic areas by retinal laser photocoagulation. Ocular adverse events (AE) have been described following the long-term administration of one or more of the drugs presently used for the treatment of SLE patients. Posterior subcapsular cataracts and secondary open-angle glaucoma are common AE of the prolonged GC administration. The long-term administration of hydroxychloroquine (HCQ) sulfate is well known to be associated with AE, such as vortex keratopathy and in particular the often irreversible and sight-threatening maculopathy. Length of administration > 5 years, > 1000 g total HCQ consumption, > 6.5 mg/kg daily dosing, coexistence of renal disease, and preexisting maculopathy are all considered risk factors for HCQ-induced retinopathy. Ocular AE of additional immunosuppressive and biological agents are still poorly known, given the worldwide more limited experience with their long-term use. A thorough ophthalmological control is strongly recommended at closer intervals for all SLE patients, in step with the total length of exposure to the drugs and the cumulative dose administered.
Literatur
1.
Zurück zum Zitat Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65:753–63.CrossRefPubMedPubMedCentral Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65:753–63.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program. Arthritis Rheumatol. 2014;66:369–78.CrossRefPubMedPubMedCentral Somers EC, Marder W, Cagnoli P, et al. Population-based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance Program. Arthritis Rheumatol. 2014;66:369–78.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Tsioni V, Andreoli L, Meini A, et al. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. Clin Exp Rheumatol. 2015;33:681–7.PubMed Tsioni V, Andreoli L, Meini A, et al. The prevalence and incidence of systemic lupus erythematosus in children and adults: a population-based study in a mountain community in northern Italy. Clin Exp Rheumatol. 2015;33:681–7.PubMed
4.
Zurück zum Zitat Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.CrossRef Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72:113–24.CrossRef
5.
6.
Zurück zum Zitat Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012;11:593–5.CrossRefPubMed Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many? Autoimmun Rev. 2012;11:593–5.CrossRefPubMed
7.
Zurück zum Zitat Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMed Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.CrossRefPubMed
8.
Zurück zum Zitat Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.CrossRefPubMed
9.
Zurück zum Zitat Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.CrossRefPubMedPubMedCentral Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004;2005(44):902–6. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2004;2005(44):902–6.
11.
Zurück zum Zitat Watson L, Leone V, Pilkington C, UK Juvenile-Onset Systemic Lupus Erythematosus Study Group, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum. 2012;64:2356–65.CrossRefPubMed Watson L, Leone V, Pilkington C, UK Juvenile-Onset Systemic Lupus Erythematosus Study Group, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum. 2012;64:2356–65.CrossRefPubMed
12.
Zurück zum Zitat Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25:1542–50.CrossRefPubMedPubMedCentral Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25:1542–50.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Arrico L, Abbouda A, Abicca I, Malagola R. Ocular complications in cutaneous lupus erythematosus: a systematic review with a meta-analysis of reported cases. J Ophthalmol. 2015;2015:254260.CrossRefPubMedPubMedCentral Arrico L, Abbouda A, Abicca I, Malagola R. Ocular complications in cutaneous lupus erythematosus: a systematic review with a meta-analysis of reported cases. J Ophthalmol. 2015;2015:254260.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Rico M, Díaz-López JB, Peña J, Oliva-Nacarino P. Latent orbital pseudotumor secondary to systemic lupus erythematosus. Clin Case Rep. 2016;4:1065–7.CrossRefPubMedPubMedCentral Rico M, Díaz-López JB, Peña J, Oliva-Nacarino P. Latent orbital pseudotumor secondary to systemic lupus erythematosus. Clin Case Rep. 2016;4:1065–7.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Ohsie LH, Murchison AP, Wojno TH. Lupus erythematosus profundus masquerading as idiopathic orbital inflammatory syndrome. Orbit. 2012;31:181–3.CrossRefPubMed Ohsie LH, Murchison AP, Wojno TH. Lupus erythematosus profundus masquerading as idiopathic orbital inflammatory syndrome. Orbit. 2012;31:181–3.CrossRefPubMed
16.
Zurück zum Zitat Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: an update for ophthalmologists. Surv Ophthalmol. 2016;61:65–82.CrossRefPubMed Papagiannuli E, Rhodes B, Wallace GR, Gordon C, Murray PI, Denniston AK. Systemic lupus erythematosus: an update for ophthalmologists. Surv Ophthalmol. 2016;61:65–82.CrossRefPubMed
18.
Zurück zum Zitat Chen A, Chen HT, Hwang YH, Chen YT, Hsiao CH, Chen HC. Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: a cross-sectional analysis. Medicine (Baltimore). 2016;95:e4218.CrossRefPubMedPubMedCentral Chen A, Chen HT, Hwang YH, Chen YT, Hsiao CH, Chen HC. Severity of dry eye syndrome is related to anti-dsDNA autoantibody in systemic lupus erythematosus patients without secondary Sjogren syndrome: a cross-sectional analysis. Medicine (Baltimore). 2016;95:e4218.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898.PubMedPubMedCentral Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898.PubMedPubMedCentral
20.
Zurück zum Zitat Caudle LE, Williams KA, Pesudovs K. The Eye Sensation Scale: an ophthalmic pain severity measure. Optom Vis Sci. 2007;84:752–62.CrossRefPubMed Caudle LE, Williams KA, Pesudovs K. The Eye Sensation Scale: an ophthalmic pain severity measure. Optom Vis Sci. 2007;84:752–62.CrossRefPubMed
21.
Zurück zum Zitat Stonecipher KG, Torkildsen GL, Ousler GW 3rd, Morris S, Villanueva L, Hollander DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887–995.CrossRefPubMedPubMedCentral Stonecipher KG, Torkildsen GL, Ousler GW 3rd, Morris S, Villanueva L, Hollander DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. Clin Ophthalmol. 2016;10:887–995.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Cordero-Coma M, Anzaar F, Sobrin L, Foster CS. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15:99–104.CrossRefPubMed Cordero-Coma M, Anzaar F, Sobrin L, Foster CS. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. Ocul Immunol Inflamm. 2007;15:99–104.CrossRefPubMed
23.
Zurück zum Zitat Holzchuh R, Villa Albers MB, et al. Two-year outcome of partial lacrimal punctal occlusion in the management of dry eye related to Sjögren syndrome. Curr Eye Res. 2011;36:507–12.CrossRefPubMed Holzchuh R, Villa Albers MB, et al. Two-year outcome of partial lacrimal punctal occlusion in the management of dry eye related to Sjögren syndrome. Curr Eye Res. 2011;36:507–12.CrossRefPubMed
24.
Zurück zum Zitat Valim V, Trevisani VF, de Sousa JM, Vilela VS, Belfort R Jr. Current approach to dry eye disease. Clin Rev Allergy Immunol. 2015;49:288–97.CrossRefPubMed Valim V, Trevisani VF, de Sousa JM, Vilela VS, Belfort R Jr. Current approach to dry eye disease. Clin Rev Allergy Immunol. 2015;49:288–97.CrossRefPubMed
25.
Zurück zum Zitat Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31:945–9.CrossRefPubMed Moscovici BK, Holzchuh R, Chiacchio BB, Santo RM, Shimazaki J, Hida RY. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31:945–9.CrossRefPubMed
26.
Zurück zum Zitat Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond). 2017;4:7.CrossRef Shoughy SS. Topical tacrolimus in anterior segment inflammatory disorders. Eye Vis (Lond). 2017;4:7.CrossRef
27.
Zurück zum Zitat Varga JH, Wolf TC. Bilateral transient keratoendotheliitis associated with systemic lupus erythematosus. Ann Ophthalmol. 1993;25:222–3.PubMed Varga JH, Wolf TC. Bilateral transient keratoendotheliitis associated with systemic lupus erythematosus. Ann Ophthalmol. 1993;25:222–3.PubMed
28.
Zurück zum Zitat Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:1757–62.CrossRef Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46:1757–62.CrossRef
29.
Zurück zum Zitat Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100:135–41.CrossRefPubMed Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100:135–41.CrossRefPubMed
30.
Zurück zum Zitat Watson P, Romano A. The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation. Eye (Lond). 2014;28:915–30.CrossRefPubMedPubMedCentral Watson P, Romano A. The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation. Eye (Lond). 2014;28:915–30.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Diogo MC, Jager MJ, Ferreira TA. CT and MR imaging in the diagnosis of scleritis. AJNR Am J Neuroradiol. 2016;37:2334–9.CrossRefPubMed Diogo MC, Jager MJ, Ferreira TA. CT and MR imaging in the diagnosis of scleritis. AJNR Am J Neuroradiol. 2016;37:2334–9.CrossRefPubMed
32.
Zurück zum Zitat Morton S, Palmer B, Muir K, Powell RJ. IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus. Ann Rheum Dis. 1998;57:660–3.CrossRefPubMedPubMedCentral Morton S, Palmer B, Muir K, Powell RJ. IgE and non-IgE mediated allergic disorders in systemic lupus erythematosus. Ann Rheum Dis. 1998;57:660–3.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic disorders in systemic lupus erythematosus: prevalence and family history. Lupus. 2002;11:426–9.CrossRefPubMed Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic disorders in systemic lupus erythematosus: prevalence and family history. Lupus. 2002;11:426–9.CrossRefPubMed
34.
Zurück zum Zitat Hsiao YP, Tsai JD, Muo CH, et al. Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations. Int J Environ Res Public Health. 2014;11:8112–22.CrossRefPubMedPubMedCentral Hsiao YP, Tsai JD, Muo CH, et al. Atopic diseases and systemic lupus erythematosus: an epidemiological study of the risks and correlations. Int J Environ Res Public Health. 2014;11:8112–22.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic diseases in systemic lupus erythematosus: prevalence and immunological considerations. Clin Exp Rheumatol. 2003;21:117–21.PubMed Sekigawa I, Yoshiike T, Iida N, Hashimoto H, Ogawa H. Allergic diseases in systemic lupus erythematosus: prevalence and immunological considerations. Clin Exp Rheumatol. 2003;21:117–21.PubMed
36.
Zurück zum Zitat Gallagher K, Viswanathan A, Okhravi N. Association of systemic lupus erythematosus with uveitis. JAMA Ophthalmol. 2015;133:1190–3.CrossRefPubMed Gallagher K, Viswanathan A, Okhravi N. Association of systemic lupus erythematosus with uveitis. JAMA Ophthalmol. 2015;133:1190–3.CrossRefPubMed
37.
Zurück zum Zitat Davies JB, Rao PK. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2008;19:512–8.CrossRefPubMed Davies JB, Rao PK. Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol. 2008;19:512–8.CrossRefPubMed
38.
Zurück zum Zitat Nishiguchi KM, Ito Y, Terasaki H. Bilateral central retinal artery occlusion and vein occlusion complicated by severe choroidopathy in systemic lupus erythematosus. Lupus. 2013;22:733–5.CrossRefPubMed Nishiguchi KM, Ito Y, Terasaki H. Bilateral central retinal artery occlusion and vein occlusion complicated by severe choroidopathy in systemic lupus erythematosus. Lupus. 2013;22:733–5.CrossRefPubMed
39.
40.
Zurück zum Zitat Lally L, Sammaritano LR. Vasculitis in antiphospholipid syndrome. Rheum Dis Clin North Am. 2015;41:109–23.CrossRefPubMed Lally L, Sammaritano LR. Vasculitis in antiphospholipid syndrome. Rheum Dis Clin North Am. 2015;41:109–23.CrossRefPubMed
41.
Zurück zum Zitat Purtscher O. Noch unbekannte befunde nach schädeltrauma. Ber Dtsch Ophthalmol Ges. 1910;36:294–301. Purtscher O. Noch unbekannte befunde nach schädeltrauma. Ber Dtsch Ophthalmol Ges. 1910;36:294–301.
42.
Zurück zum Zitat Agrawal A, McKibbin MA. Purtscher’s and Purtscher-like retinopathies: a review. Surv Ophthalmol. 2006;51:129–36.CrossRefPubMed Agrawal A, McKibbin MA. Purtscher’s and Purtscher-like retinopathies: a review. Surv Ophthalmol. 2006;51:129–36.CrossRefPubMed
43.
Zurück zum Zitat Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am J Ophthalmol. 2014;158:1335–41.CrossRefPubMed Wu C, Dai R, Dong F, Wang Q. Purtscher-like retinopathy in systemic lupus erythematosus. Am J Ophthalmol. 2014;158:1335–41.CrossRefPubMed
44.
Zurück zum Zitat Kunavisarut P, Pathanapitoon K, Rothova A. Purtscher-like retinopathy associated with systemic lupus erythematosus. Ocul Immunol Inflamm. 2016;24:60–8.PubMed Kunavisarut P, Pathanapitoon K, Rothova A. Purtscher-like retinopathy associated with systemic lupus erythematosus. Ocul Immunol Inflamm. 2016;24:60–8.PubMed
45.
Zurück zum Zitat Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9:288–98.CrossRefPubMed Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9:288–98.CrossRefPubMed
46.
Zurück zum Zitat Han YS, min Yang C, Lee SH, Shin JH, Moon SW, Kang JH. Secondary angle closure glaucoma by lupus choroidopathy as an initial presentation of systemic lupus erythematosus: a case report. BMC Ophthalmol. 2015;15:148.CrossRefPubMedPubMedCentral Han YS, min Yang C, Lee SH, Shin JH, Moon SW, Kang JH. Secondary angle closure glaucoma by lupus choroidopathy as an initial presentation of systemic lupus erythematosus: a case report. BMC Ophthalmol. 2015;15:148.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Balci O, Jeannin B, Herbort CP Jr. Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2017;. https://doi.org/10.1007/s10792-017-0487-5 [Epub ahead of print]. Balci O, Jeannin B, Herbort CP Jr. Contribution of dual fluorescein and indocyanine green angiography to the appraisal of posterior involvement in birdshot retinochoroiditis and Vogt–Koyanagi–Harada disease. Int Ophthalmol. 2017;. https://​doi.​org/​10.​1007/​s10792-017-0487-5 [Epub ahead of print].
48.
Zurück zum Zitat Edouard S, Douat J, Sailler L, Arlet P, Astudillo L. Bilateral choroidopathy in systemic lupus erythematosus. Lupus. 2011;20:1209–10.CrossRefPubMed Edouard S, Douat J, Sailler L, Arlet P, Astudillo L. Bilateral choroidopathy in systemic lupus erythematosus. Lupus. 2011;20:1209–10.CrossRefPubMed
49.
Zurück zum Zitat Gharbiya M, Pecci G, Baglio V, Gargiulo A, Allievi F, Balacco-Gabrieli C. Indocyanine green angiographic findings for patients with systemic lupus erythematosus nephropathy. Retina. 2006;26:159–64.CrossRefPubMed Gharbiya M, Pecci G, Baglio V, Gargiulo A, Allievi F, Balacco-Gabrieli C. Indocyanine green angiographic findings for patients with systemic lupus erythematosus nephropathy. Retina. 2006;26:159–64.CrossRefPubMed
50.
Zurück zum Zitat Magro Checa C, Cohen D, Bollen EL, van Buchem MA, Huizinga TW, Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013;27:405–24.CrossRefPubMed Magro Checa C, Cohen D, Bollen EL, van Buchem MA, Huizinga TW, Steup-Beekman GM. Demyelinating disease in SLE: is it multiple sclerosis or lupus? Best Pract Res Clin Rheumatol. 2013;27:405–24.CrossRefPubMed
51.
Zurück zum Zitat Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol. 2009;87:204–10.CrossRefPubMed Lin YC, Wang AG, Yen MY. Systemic lupus erythematosus-associated optic neuritis: clinical experience and literature review. Acta Ophthalmol. 2009;87:204–10.CrossRefPubMed
52.
Zurück zum Zitat Frigui M, Frikha F, Sellemi D, Chouayakh F, Feki J, Bahloul Z. Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. Lupus. 2011;20:1214–8.CrossRefPubMed Frigui M, Frikha F, Sellemi D, Chouayakh F, Feki J, Bahloul Z. Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. Lupus. 2011;20:1214–8.CrossRefPubMed
53.
Zurück zum Zitat Suri D, Abujam B, Gupta A, et al. Optic nerve involvement in childhood onset systemic lupus erythematosus: three cases and a review of the literature. Lupus. 2016;25:93–6.CrossRefPubMed Suri D, Abujam B, Gupta A, et al. Optic nerve involvement in childhood onset systemic lupus erythematosus: three cases and a review of the literature. Lupus. 2016;25:93–6.CrossRefPubMed
56.
Zurück zum Zitat Migliaresi S, Di Iorio G, Picillo U, et al. Neurological manifestations of systemic lupus erythematosus. Study of 53 cases. Ann Ital Med Int. 1989;4:10–5.PubMed Migliaresi S, Di Iorio G, Picillo U, et al. Neurological manifestations of systemic lupus erythematosus. Study of 53 cases. Ann Ital Med Int. 1989;4:10–5.PubMed
57.
Zurück zum Zitat Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol. 1995;52:1145–9.CrossRefPubMed Keane JR. Eye movement abnormalities in systemic lupus erythematosus. Arch Neurol. 1995;52:1145–9.CrossRefPubMed
58.
Zurück zum Zitat Alonso-Valdivielso JL, Alvarez Lario B, Alegre López J, Sedano Tous MJ, Buitrago Gómez A. Acquired Brown’s syndrome in a patient with systemic lupus erythematosus. Ann Rheum Dis. 1993;52:63–4.CrossRefPubMedPubMedCentral Alonso-Valdivielso JL, Alvarez Lario B, Alegre López J, Sedano Tous MJ, Buitrago Gómez A. Acquired Brown’s syndrome in a patient with systemic lupus erythematosus. Ann Rheum Dis. 1993;52:63–4.CrossRefPubMedPubMedCentral
59.
61.
Zurück zum Zitat Abel MP, Murphy FT, Enzenauer RJ, Enzenauer RW. Internuclear ophthalmoplegia (INO): an unusual presentation of neuropsychiatric lupus erythematosus. Binocul Vis Strabismus Q. 2003;18:29–30.PubMed Abel MP, Murphy FT, Enzenauer RJ, Enzenauer RW. Internuclear ophthalmoplegia (INO): an unusual presentation of neuropsychiatric lupus erythematosus. Binocul Vis Strabismus Q. 2003;18:29–30.PubMed
63.
Zurück zum Zitat Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. Int J Rheum Dis. 2014;17:494–501.PubMed Man BL, Mok CC, Fu YP. Neuro-ophthalmologic manifestations of systemic lupus erythematosus: a systematic review. Int J Rheum Dis. 2014;17:494–501.PubMed
64.
Zurück zum Zitat Katsuyama E, Sada KE, Tatebe N, et al. Bilateral abducens nerve palsy due to idiopathic intracranial hypertension as an initial manifestation of systemic lupus erythematosus. Intern Med. 2016;55(8):991–4.CrossRefPubMed Katsuyama E, Sada KE, Tatebe N, et al. Bilateral abducens nerve palsy due to idiopathic intracranial hypertension as an initial manifestation of systemic lupus erythematosus. Intern Med. 2016;55(8):991–4.CrossRefPubMed
65.
Zurück zum Zitat Castrejón I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32(Suppl 85):S-85–95. Castrejón I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32(Suppl 85):S-85–95.
66.
Zurück zum Zitat Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97–107.CrossRefPubMed Xiong W, Lahita RG. Pragmatic approaches to therapy for systemic lupus erythematosus. Nat Rev Rheumatol. 2014;10:97–107.CrossRefPubMed
67.
Zurück zum Zitat Mosca M, Tani C, Aringer M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev. 2011;10:383–8.CrossRefPubMedPubMedCentral Mosca M, Tani C, Aringer M, et al. Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. Autoimmun Rev. 2011;10:383–8.CrossRefPubMedPubMedCentral
68.
Zurück zum Zitat Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009;20:308–17.CrossRefPubMed Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009;20:308–17.CrossRefPubMed
69.
Zurück zum Zitat Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol. 2013;91:604–9.CrossRefPubMed Ho WL, Wong H, Yau T. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol. 2013;91:604–9.CrossRefPubMed
70.
Zurück zum Zitat Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv Ophthalmol. 2014;59:493–502.CrossRefPubMed Kheir WJ, Sniegowski MC, El-Sawy T, Li A, Esmaeli B. Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy. Surv Ophthalmol. 2014;59:493–502.CrossRefPubMed
72.
Zurück zum Zitat Fel A, Aslangul E, Le Jeunne C. Indications et complications des corticoïdes en ophtalmologie. Presse Med. 2012;41:414–21.CrossRefPubMed Fel A, Aslangul E, Le Jeunne C. Indications et complications des corticoïdes en ophtalmologie. Presse Med. 2012;41:414–21.CrossRefPubMed
73.
Zurück zum Zitat Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32:1071–3.CrossRefPubMed Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32:1071–3.CrossRefPubMed
74.
Zurück zum Zitat van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913–9.CrossRefPubMed van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913–9.CrossRefPubMed
75.
Zurück zum Zitat Bollinger K, Kim J, Lowder CY, Kaiser PK, Smith SD. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology. 2011;118:1927–31.CrossRefPubMed Bollinger K, Kim J, Lowder CY, Kaiser PK, Smith SD. Intraocular pressure outcome of patients with fluocinolone acetonide intravitreal implant for noninfectious uveitis. Ophthalmology. 2011;118:1927–31.CrossRefPubMed
76.
Zurück zum Zitat Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22:517–22.CrossRefPubMed Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011;22:517–22.CrossRefPubMed
77.
Zurück zum Zitat Dosso A, Rungger-Brändle E. In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:318–20.CrossRefPubMed Dosso A, Rungger-Brändle E. In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:318–20.CrossRefPubMed
78.
Zurück zum Zitat Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 2008;23:201–9.CrossRefPubMed Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmol. 2008;23:201–9.CrossRefPubMed
79.
Zurück zum Zitat Payne JF, Hubbard GB 3rd, Aaberg TM Sr, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2011;95:245–50.CrossRefPubMed Payne JF, Hubbard GB 3rd, Aaberg TM Sr, Yan J. Clinical characteristics of hydroxychloroquine retinopathy. Br J Ophthalmol. 2011;95:245–50.CrossRefPubMed
80.
Zurück zum Zitat Modi YS, Singh RP, Fine HF. Hydroxychloroquine: a brief review on screening, toxicity, and progression. Ophthalmic Surg Lasers Imaging Retina. 2016;47:207–17.CrossRefPubMed Modi YS, Singh RP, Fine HF. Hydroxychloroquine: a brief review on screening, toxicity, and progression. Ophthalmic Surg Lasers Imaging Retina. 2016;47:207–17.CrossRefPubMed
81.
Zurück zum Zitat Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110:1321–6.CrossRefPubMed Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110:1321–6.CrossRefPubMed
82.
Zurück zum Zitat Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–60.CrossRefPubMed Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–60.CrossRefPubMed
83.
Zurück zum Zitat Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132:1105–12.CrossRefPubMed Marmor MF, Hu J. Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol. 2014;132:1105–12.CrossRefPubMed
84.
Zurück zum Zitat Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol. 2013;131:1187–97.CrossRefPubMed Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA. Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol. 2013;131:1187–97.CrossRefPubMed
85.
Zurück zum Zitat Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968–78.CrossRefPubMed Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968–78.CrossRefPubMed
86.
Zurück zum Zitat Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94.CrossRefPubMed Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94.CrossRefPubMed
87.
Zurück zum Zitat Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–28.CrossRefPubMed Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155:418–28.CrossRefPubMed
88.
Zurück zum Zitat Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014;132:1199–208.CrossRefPubMedPubMedCentral Nika M, Blachley TS, Edwards P, Lee PP, Stein JD. Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol. 2014;132:1199–208.CrossRefPubMedPubMedCentral
89.
Zurück zum Zitat Klemencic S. Cotton wool spots as an indicator of methotrexate-induced blood dyscrasia. Optometry. 2010;81:177–80.CrossRefPubMed Klemencic S. Cotton wool spots as an indicator of methotrexate-induced blood dyscrasia. Optometry. 2010;81:177–80.CrossRefPubMed
90.
Zurück zum Zitat Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol. 2012;51:29–46.CrossRefPubMed Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol. 2012;51:29–46.CrossRefPubMed
91.
Zurück zum Zitat Apaydin C, Gur B, Yakupoglu G, Saka O. Ocular and visual side effects of systemic cyclosporine. Ann Ophthalmol. 1992;24:465–9.PubMed Apaydin C, Gur B, Yakupoglu G, Saka O. Ocular and visual side effects of systemic cyclosporine. Ann Ophthalmol. 1992;24:465–9.PubMed
92.
Zurück zum Zitat Steg RE, Garcia EG. Complex visual hallucinations and cyclosporine neurotoxicity. Neurology. 1991;41:1156.CrossRefPubMed Steg RE, Garcia EG. Complex visual hallucinations and cyclosporine neurotoxicity. Neurology. 1991;41:1156.CrossRefPubMed
93.
Zurück zum Zitat Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs. 2014;28:211–28.CrossRefPubMed Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs. 2014;28:211–28.CrossRefPubMed
94.
Zurück zum Zitat Ugarte-Gil MF, Alarcón GS. Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol. 2014;33:441–50.CrossRefPubMed Ugarte-Gil MF, Alarcón GS. Systemic lupus erythematosus: a therapeutic challenge for the XXI century. Clin Rheumatol. 2014;33:441–50.CrossRefPubMed
96.
Zurück zum Zitat Clowse ME, Wallace DJ, Furie RA, et al. EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69:362–75.CrossRefPubMedPubMedCentral Clowse ME, Wallace DJ, Furie RA, et al. EMBODY Investigator Group. Efficacy and safety of epratuzumab in moderately to severely active systemic lupus erythematosus: results from two phase III randomized, double-blind, placebo-controlled trials. Arthritis Rheumatol. 2017;69:362–75.CrossRefPubMedPubMedCentral
97.
Zurück zum Zitat Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE Randomised Trial). Ann Rheum Dis. 2015;74:2006–15.CrossRefPubMed Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE Randomised Trial). Ann Rheum Dis. 2015;74:2006–15.CrossRefPubMed
98.
Zurück zum Zitat Furie RA, Leon G, Thomas M, et al. PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667–75.CrossRefPubMed Furie RA, Leon G, Thomas M, et al. PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis. 2015;74:1667–75.CrossRefPubMed
99.
Zurück zum Zitat Furie R, Khamashta M, Merrill JT, et al. CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–86.CrossRefPubMedPubMedCentral Furie R, Khamashta M, Merrill JT, et al. CD1013 Study Investigators. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 2017;69:376–86.CrossRefPubMedPubMedCentral
Metadaten
Titel
Systemic lupus erythematosus and ocular involvement: an overview
verfasst von
Rosanna Dammacco
Publikationsdatum
14.12.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 2/2018
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-017-0479-9

Weitere Artikel der Ausgabe 2/2018

Clinical and Experimental Medicine 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.